Trends in prescribing proton pump inhibitors in Taiwan: 1997 - 2000

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 5, 2003, Pages 207-212

  Chen, T J ^a   Chou, L F ^b   Hwang, S J ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

combination therapy; Drug utilization; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DEVELOPING COUNTRY; DRUG UTILIZATION; ERADICATION THERAPY; FEMALE; HEALTH PROGRAM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL PATIENT; HUMAN; MALE; NATIONAL HEALTH INSURANCE; OUTPATIENT DEPARTMENT; PRESCRIPTION; SEX DIFFERENCE; TAIWAN; UTILIZATION REVIEW;

EID: 0037951309     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41207     Document Type: Article

References (14)

1. Bashford JNR, Norwood J, Chapman SR 1998 Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 317: 452-456
2. Bateman DN 1997 Proton-pump inhibitors: three of a kind? Lancet 349: 1637-1638
3. Cromwell DM, Bass EB, Steinberg EP, Yasui Y, Ravich WJ, Hendrix TR, McLeod SF Moore RD 1999 Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations? Health Serv Res 33: 1593-1610
4. DeVault KR, Castell DO 1999 Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 94: 1434-1442
5. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G 2000 A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 95: 395-407
6. Howden CW, Hunt RH 1998 Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 93: 2330-2338
7. Jones MI, Greenfield SH, Jowett S, Bradley CP, Seal R 2001 Proton pump inhibitors: a study of GPs' prescribing. Fam Pract 18: 333-338
8. Kuipers EJ, Lundell L, Klinkenherg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CBHW, Jansen JBMJ, Dalenback J, Snel P, Nelis GF, Meuwissen SGM 1996 Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334: 1018-1022
9. McManus P, Marley J, Birkett DJ, Lindner J 1998 Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 46: 409-411
10. O'Connor JB, Provenzale D, Brazer S 2000 Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 95: 3356-3364
11. Ofman JJ, Dorn GH, Fennerty MB, Fass R 2002 The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16: 261-273
12. Pollock K, Grime J 2000 Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self-regulation of treatment may be an under-exploited resource. Soc Sci Med 51: 1827-1839
13. Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, Wang WC 2002 Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 16: 291-296
14. Soll AH 1996 Medical treatment of peptic ulcer disease: practice guidelines. JAMA 275: 622-629